NVST vs SOLV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SOLV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVST and SOLV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVST and SOLV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Envista Holdings Corporation is a Brea, California dental products maker spun out of Danaher in 2019, selling into more than 130 countries through roughly 30 brands: Nobel Biocare and Implant Direct in implants, Ormco and Spark in orthodontics, DEXIS in imaging, and Kerr in consumables. Two reporting segments carry the business. Specialty Products & Technologies (implants, prosthetics, brackets, aligners, lab products) generated ~$1.75 billion of 2025 sales, while Equipment & Consumables (imaging systems and software, bonding agents, rotary burs, endodontic systems, infection prevention) generated ~$967 million. Around 85% of revenue comes from consumables, services and spare parts rather than capital equipment, which gives the top line a recurring shape even in quarters when dentists defer large purchases. By region, North America contributed ~$1.40 billion of 2025 sales, Western Europe ~$615 million, and emerging markets ~$586 million.

Full NVST guide

Solventum is a healthcare company that was spun off from 3M in 2024, combining 3M's former Health Care business into a standalone public company. It operates across several healthcare segments: medical surgical products (wound care, advanced dressings, surgical supplies, infection prevention), dental and orthodontic solutions, health information systems (clinical documentation, coding, and revenue-cycle software for hospitals), and purification and filtration (including water and biopharma filtration). The company makes money selling consumable medical products to hospitals and clinics, software and services to health systems, and filtration technology to industrial and life-science customers. As a recent spin-off, Solventum's story centers on standing up independent operations, paying down debt inherited at separation, stabilizing growth, and improving margins. It holds established brands and large installed bases in several niches. Headquartered in Maplewood, Minnesota, it serves customers across hospital, dental, and industrial end markets globally.

Full SOLV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVST drivers: Margin repair from a low base; Implants and aligners as the profit pool.
• SOLV drivers: Recurring consumable and software revenue; Spin-off self-help and margin expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Dental treatment is deferrable, and the 2024 collapse showed how fast patient traffic and practice capital budgets can move against this business. For SOLV, as a recent spin-off, Solventum carries meaningful debt taken on at separation and must prove it can grow organically after years inside 3M, where the business reportedly underinvested.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVST if you believe its drivers more; SOLV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVST and SOLV guides.

NVST. Two very different multiples describe the same stock: about 49x trailing GAAP earnings, and about 18x the midpoint of management's 2026 adjusted EPS guidance. Bridging them are amortization of acquired intangibles, restructuring charges, and a 2025 effective tax rate near 73% created by US pre-tax losses sitting alongside $203.9 million of international pre-tax income. At roughly 1.6x trailing sales and 1.5x book value, the market is not paying a premium on revenue or assets, the usual shape for a company whose reported earnings lag its operating improvement.

SOLV. Solventum trades at a discount to faster-growing medtech peers, reflecting its slow top-line growth, elevated post-spin debt, and the work still required to prove independent execution. The qualitative profile is a turnaround and self-help story: stabilize growth, reduce leverage, and expand margins. Successful deleveraging and portfolio reshaping are the key swing factors.

Headline figures (approximate, August 2026): NVST shows revenue (ttm) ~$2.86 billion, market cap ~$4.44 billion (~$27.70 per share, ~160.6 million shares), adjusted diluted eps (ttm) ~$1.46 vs ~$0.58 on a GAAP basis, forward p/e on 2026 adjusted eps guidance ~18x ($1.50 to $1.55); SOLV shows revenue (ttm) ~$8 billion, revenue growth low-single-digit, roughly flat to slightly up, operating margin ~20% on an adjusted basis, net debt elevated, inherited at the 3M separation.

NVST and SOLV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVST and SOLV exposure against your real portfolio. It is not an investment adviser.